Brief: ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114

ORIC Pharmaceuticals

13/01/2025 14:21

Jan 13 (Reuters) - Oric Pharmaceuticals Inc  ORIC.O :
    * ORIC PHARMACEUTICALS ANNOUNCES CLINICAL SUPPLY AGREEMENT
TO
EVALUATE ORIC-114 IN COMBINATION WITH AMIVANTAMAB FOR THE
FIRST-LINE TREATMENT OF NSCLC WITH EGFR EXON 20 INSERTION
MUTATIONS
    * ORIC PHARMACEUTICALS INC - ENTERS SUPPLY AGREEMENT WITH
JANSSEN
TO EVALUATE ORIC-114
    * ORIC PHARMACEUTICALS INC - TO CONDUCT AND SPONSOR TRIAL;
J&J TO
PROVIDE SC AMIVANTAMAB
    * ORIC PHARMACEUTICALS INC - TO INITIATE PHASE 1B TRIAL FOR
ORIC-114 IN Q1 2025
    * ORIC PHARMACEUTICALS INC - EXPECTS TO REPORT INITIAL TRIAL
DATA
IN MID-2026

Source text:  ID:nGNX2gcP3N 
Further company coverage:  ORIC.O 

 ((Reuters.Briefs@thomsonreuters.com;))